EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Characteristics and Outcomes of Fetal Cardiac Rhabdomyoma With or Without mTOR Inhibitors, a Systematic Review and Meta‐Analysis

Hiba J Mustafa iD, Ali Javinani, Makayla L Morning, Francesco D'Antonio iD, Giorgio Pagani, Poonam M Puranik, Asma Khalil iD, Alireza A Shamshirsaz

Prenatal Diagnosis · 2024-09 · 44 (10) · 1251-1267

DOI: 10.1002/pd.6640 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Prenatal Diagnosis, online erschienen am 20.08.2024. Verfasst von Hiba J Mustafa und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Fetal Center at Riley Children's and Indiana University Health, Division of Maternal-Fetal Medicine, Indiana University School of Medicine, India…. Hauptthemen laut MEDLINE: Heart Neoplasms, Rhabdomyoma, MTOR Inhibitors. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the characteristics and outcomes of fetal cardiac rhabdomyoma with or without prenatal use of mammalian target of rapamycin inhibitor (mTORi). Search Strategy We systematically searched PubMed, Scopus, and Web of Science until June 2023. Selection Criteria Studies reporting on pregnancies with fetal cardiac rhabdomyoma were included. Data Collection and Analysis A meta‐analysis of proportions was conducted only on studies that included three or more cases.

Results

A systematic review included 61 studies reporting on 400 fetuses with cardiac rhabdomyoma, of which 52 studies (389 fetuses) had expectant management and 9 studies (11 fetuses) were managed with mTORi. The meta‐analysis included 26 studies reporting on 354 fetuses. Prenatally, 14% (95% CI 4–36) had pericardial effusion, 13% (95% CI 6–27) had arrhythmia, 16% (95% CI 7–31) had outflow tract obstruction, and 10% (95% CI 4–21) had hydrops. Fetal demise occurred in 12% (95% CI 5–30). Before delivery, tumor size reduction was noted in 13%, and after birth in 58%. Following birth, 8% (95% CI 3–14) had neonatal death and 9% (95% 4–17) required cardiac surgery. 60% (95% CI 41–79) of cases were diagnosed with tuberous sclerosis. Seizures were reported only in cases with a tuberous sclerosis diagnosis (41/71 infants). For the 9 studies reporting all together on 11 fetuses with tuberous sclerosis receiving prenatal mTORi, they showed improvement in the size of cardiac rhabdomyoma as well as outflow obstruction and none had fetal demise or neonatal death, and none required postnatal cardiac surgery.

Conclusions

We report on the natural history of prenatal cardiac rhabdomyoma, including characteristics, progression, and survival. We report 11 fetuses with tuberous sclerosis and cardiac rhabdomyoma receiving prenatal mTORi, showing promising results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart NeoplasmsRhabdomyomaMTOR InhibitorsHumansPregnancyFemaleFetal DiseasesInfant, NewbornTOR Serine-Threonine Kinases

Substanzen

MTOR InhibitorsTOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • The Fetal Center at Riley Children's and Indiana University Health, Division of Maternal-Fetal Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Maternal Fetal Care Center, Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Obstetric and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Center for Fetal Care and High-Risk Pregnancy, Department of Obstetrics and Gynecology, University Hospital of Chieti, Chieti, Italy.
  • Maternal Fetal Medicine Unit, Department of Obstetrics and Gynecology, ASST-Papa Giovanni XXIII, Bergamo, Italy.
  • Pediatric Cardiology, Riley Hospital for Children and Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Hiba J Mustafa, Francesco D'Antonio, Asma Khalil

Zitieren

APA

Mustafa, H. J., Javinani, A., Morning, M. L., D'Antonio, F., Pagani, G., Puranik, P. M., Khalil, A., & Shamshirsaz, A. A. (2024). Characteristics and Outcomes of Fetal Cardiac Rhabdomyoma With or Without mTOR Inhibitors, a Systematic Review and Meta‐Analysis. Prenatal Diagnosis, 44(10), 1251-1267. https://doi.org/10.1002/pd.6640

Vancouver

Mustafa HJ, Javinani A, Morning ML, D'Antonio F, Pagani G, Puranik PM, et al. Characteristics and Outcomes of Fetal Cardiac Rhabdomyoma With or Without mTOR Inhibitors, a Systematic Review and Meta‐Analysis. Prenatal Diagnosis. 2024;44(10):1251-1267. doi:10.1002/pd.6640

BibTeX
@article{Mustafa2024,
  author = {Mustafa, Hiba J and Javinani, Ali and Morning, Makayla L and D'Antonio, Francesco and Pagani, Giorgio and Puranik, Poonam M and Khalil, Asma and Shamshirsaz, Alireza A},
  title = {Characteristics and Outcomes of Fetal Cardiac Rhabdomyoma With or Without mTOR Inhibitors, a Systematic Review and Meta‐Analysis},
  journal = {Prenatal Diagnosis},
  year = {2024},
  volume = {44},
  number = {10},
  pages = {1251--1267},
  doi = {10.1002/pd.6640}
}
Kostenlos starten →